L eft ventricular (LV) papillary muscles play an important role in both cardiac and mitral valve functions.
1,2 Ischemia affecting the blood supply to the papillary muscles can result in infarction and subsequent dysfunction of the papillary muscles. Previous single-center studies consistently demonstrated a relatively high incidence of papillary muscle infarctions (PapMI; 26%-53%) after acute myocardial infarction (MI). [3] [4] [5] [6] [7] [8] Furthermore, numerous studies assessed the effects of PapMI on LV morphology and mitral regurgitation (MR), demonstrating that isolated PapMI rarely results in relevant MR and that the predominant mechanism of MR may involve both ischemic papillary muscle dysfunction and valvular dysfunction from LV dilation and dyssynchronous myocardial contraction. infarcted papillary muscles have been reported to be arrhythmogenic and are associated with postinfarction ventricular arrhythmias. 15 Consequently, a large-scale multicenter study is required to investigate the effect of PapMI on prognosis in patients with MI in the current reperfusion era.
Late gadolinium enhancement (LGE) cardiac MRI (CMR) is the current gold standard for noninvasive imaging of myocardial necrosis and has the unique advantage of visualization of even microinfarctions at high spatial resolution. 16, 17 Therefore, CMR creates a unique opportunity to assess PapMI with high precision in vivo.
The aim of this study was (1) to assess the incidence and clinical characteristics of PapMI in a large multicenter cohort of patients with ST-segment-elevation MI (STEMI) and (2) to determine the prognostic significance of PapMI on hard clinical outcomes (death, reinfarction, and readmission for acute onset of congestive heart failure) at 1-year follow-up.
Methods

Study Design
This prospective CMR study was a predefined substudy of the Abciximab Intracoronary versus intravenously Drug Application in STEMI (AIDA STEMI) trial that compared intravenous versus intracoronary abciximab application in patients with STEMI and did not show a difference in infarct size, reperfusion injury, and clinical outcome between the treatment groups. 18, 19 The detailed design and main results of the trial have previously been published. [18] [19] [20] Briefly, AIDA STEMI was a randomized, open-label, multicenter trial. Patients presenting with STEMI in the first 12 hours after symptom onset were randomly assigned in a 1:1 ratio by a central Web-based randomization system to intracoronary versus intravenous abciximab bolus (0.25 mg/kg bodyweight) during primary percutaneous coronary intervention with a subsequent 12-hour intravenous infusion at 0.125 μg/kg per minute (maximum 10 μg/min).
Patients were enrolled at 22 sites in Germany, with a final enrolled trial population of 2065 patients (intracoronary abciximab [n=1032] and intravenous abciximab [n=1033]). The study was approved by national regulatory authorities and ethics committees of participating centers. All patients provided written informed consent.
PapMI CMR Substudy
Consecutive patients enrolled in the AIDA STEMI trial at 8 sites were included in the CMR substudy. 19 The sites were chosen based on proven expertise in performing CMR examinations in patients with acute MI. By protocol, CMR was performed on days 1 to 10 after the index event for the assessment of PapMI, myocardial salvage, infarct size, presence and extent of microvascular obstruction, LV ejection fraction, and end-systolic and end-diastolic volumes.
The detailed scan protocol on a clinical 1.5 or 3.0-T CMR scanner has been described previously. 19, 20 Images were sent on storable media to the CMR core laboratory at the University of Leipzig, Heart Center, Germany, for assessment by fully blinded operators.
CMR Image Analysis
For all quantitative analyses, certified CMR evaluation software was used (cmr42 Circle Cardiovascular Imaging Inc, Calgary, Alberta, Canada). Semiautomated computer-aided threshold detection was used to identify regions of edema, hypointense cores, microvascular obstruction, and infarcted myocardium, as previously described. PapMI was evaluated by LGE CMR images from 3 different views (short-axis, 2-chamber, and 4-chamber views). Cine images of the same location were used as a side-by-side reference for localizing the papillary muscle within the blood pool during interpretation of contrast-enhanced images (Figure 1 ). The signal intensity of both anterior and posterior papillary muscles was measured and compared with that of remote noninfarcted LV myocardium. Papillary muscles with signal intensity 2 SD above the mean signal obtained in the remote noninfarcted myocardium, in ≥3 consecutive slices in the shortaxis and corresponding 2-and 4-chamber views, were considered as infarcted, as previously described. 4 The CMR core laboratory is highly experienced in CMR acquisition and postprocessing with excellent reproducibility and low inter-and intraobserver variability for infarct size and myocardial salvage assessment.
21,22
Echocardiography
Transthoracic echocardiography using Vivid-7 ultrasound equipment (GE, Milwaukee, WI) was the reference for MR assessment and was performed by experienced observers blinded to clinical data and other imaging tests according to standard clinical practice in concordance with American Society of Echocardiography recommendations. 23 Color flow imaging with the MR jet area-to-left atrium area ratio was used for an initial screening to assess the presence and severity of MR. In patients with more than trace regurgitation, the regurgitant orifice area was calculated by the proximal isovelocity surface area method, as previously described. 4, 23 The severity of MR was graded using established cutoffs in accordance with American Society of Echocardiography guidelines (mild, regurgitant fraction <30%; moderate, 30%-39%; moderate/severe, 40%-49%; and severe, ≥50%).
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Clinical End Points
The primary clinical end point of this substudy was a composite of all-cause death, reinfarction, and new congestive heart failure within 1 year after infarction. All components of the combined clinical end point were adjudicated by a clinical end point committee, blinded to the patient's assigned treatment, based on data provided by the clinical trial sites. To avoid double counting of patients with >1 event, each patient contributed only once to the composite major adverse cardiac event (MACE) end point (death>reinfarction>congestive heart failure). Detailed outcome definitions have been reported previously. 20 In brief, reinfarction occurring <24 hours of the index event was defined as symptoms persisting for >30 minutes plus new STEMI. Reinfarction >24 hours after the index event was included when symptoms >30-minute duration occurred in combination with an increase in creatine kinase-myocardial band or troponin concentration above the reference limit in patients whose values had returned to normal or when an increase of ≥50% from the last non-normalized measurement occurred.
New congestive heart failure was defined as any new diagnosis of congestive heart failure ≥24 hours after randomization with ≥1 of the following disorders necessitating treatment with diuretics: cardiogenic shock, pulmonary edema or congestion on chest radiograph, rales >1/3 from lung base (Killip class ≥2), pulmonary capillary wedge >25 mm Hg, and dyspnea with oxygen saturation <90% without supplemental oxygen in the absence of lung disease. In patients discharged after the index event, any congestive heart failure necessitating readmission to hospital was recorded.
Statistical Analysis
Baseline patient characteristics, procedural details, and CMR findings are described according to the presence or absence of PapMI. Data for continuous variables are presented in medians with 25th and 75th percentiles. Categorical variables are presented as frequencies and percentages. Testing for treatment differences was performed with Wilcoxon rank-sum tests for continuous variables and χ 2 tests for categorical variables.
Univariate and stepwise multivariate logistic regression analyses were performed to identify the predictors of PapMI, as well as the presence and severity of MR. Multivariate regression was performed using only variables with a P<0.05 in univariate regression analyses. For univariate analyses, all variables of Table 1 were investigated.
The Kaplan-Meier method was used to illustrate the timing of events during 12-month follow-up according to the presence or absence of PapMI; statistical assessment was performed using the logrank test. Simple Cox regression analysis was used to identify the predictors of MACE during 12 months. Significant variables (P<0.05) were then tested in a stepwise multiple Cox regression analysis. A 2-tailed P<0.05 was defined as statistically significant. SPSS version 20.0 was used for statistical analyses. Figure 1 ). In 55 patients (53%) the papillary muscle was completely infarcted, and in 49 patients (47%) incomplete infarction of the papillary muscles was detected.
Results
From
Patient Characteristics
Demographic and clinical characteristics are presented in Table 1 . The median age of the overall enrolled population was 62 (interquartile range, 51-71) years, and 559 (76%) patients were men. Cardiovascular risk factors and reperfusion times were similar between groups. Patients with PapMI had significantly more often multivessel coronary artery disease (P=0.01) and right coronary artery and left circumflex culprit lesions (P<0.001). Consequently, anterior infarctions were significantly less frequent in the PapMI group (P<0.001; Table 1 ). All other prescribed drugs and study procedures were similar for both groups.
The association of infarcted papillary muscle (anterior, posterior, bilateral) with the location of the culprit lesion is displayed in Figure 3 . Patients with anterior PapMI had most often left anterior descending culprit lesions, whereas in patients with posterior PapMI the culprit site was most often the right coronary artery. Among patients with infarction of both papillary muscles, the culprit site was most often the left circumflex artery.
CMR Findings
The median time between the index event and CMR was 3 days (interquartile range, 2-4 days) for both groups (P=0.70). Most patients underwent CMR on a 1.5-T scanner (97%). The main findings from CMR analyses are presented in Table 2 .
The presence of PapMI was associated with larger infarcts (P<0.001), less myocardial salvage (P<0.001), and impaired LV function (P<0.001). Microvascular obstruction was identified in 348 (48%) patients with a significantly higher occurrence (59% versus 46%; P=0.02) and extent (P=0.046) in patients with PapMI (Table 2 ). There was also a significant higher incidence of intramyocardial hemorrhage in the PapMI group (P=0.02).
Predictors of PapMI and Presence of MR
Multivariate analyses were performed to assess the independent prognostic factors for the occurrence of PapMI. Significant predictors are displayed in Table 3 .
There was no significant univariate relationship between the presence of PapMI and MR (odds ratio, Figure 4B ).
Patients with bilateral infarction had no higher risk for MACE compared with patients with unilateral PapMI (bilateral PapMI 3 events [15%] versus unilateral PapMI 18 events [21%]; P=0.52).
In addition to PapMI, several established markers of increased patient risk were associated with an increased MACE rate at 1-year follow-up by simple Cox regression analysis (Table 4) . Using stepwise multiple Cox regression analysis, only PapMI, age, Killip class on admission, and LV ejection fraction emerged as independent predictors of MACE (Table 5) . Although the presence of MR had an unadjusted association with MACE, it did not predict clinical events independently in multivariable Cox regression analysis.
Discussion
To our best knowledge, this is the first multicenter and by far largest CMR study to date to assess the prognostic significance of PapMI on hard clinical outcome in acute reperfused STEMI. The major findings are as follows: (1) patients with PapMI have a significantly higher mortality and MACE rate at 12-month follow-up; (2) the occurrence of PapMI is mainly associated with the presence and extent of severe myocardial (4) PapMI is an independent predictor of MACE at 12-month follow-up. Thus, the detection of PapMI is clinically important with prognostic implications.
Incidence and Clinical Characteristics of PapMI
In recent years, CMR has emerged as the clinically most feasible and accurate noninvasive tool to quantify myocardial necrosis and infarct size. The high spatial resolution of CMR enables visualization of even microinfarctions, involving as little as 1 g of tissue, and it is, therefore, ideally suited to detect PapMI accurately in patients with MI. 16, 17 However, there are only few small single-center studies evaluating the incidence and clinical characteristics of patients with PapMI using CMR. These studies reported an incidence of PapMI ranging from 26% to 53%. [3] [4] [5] [6] [7] [8] In autopsy studies, papillary muscle necrosis was documented in 19% to 32% of patients with MI. 24, 25 In our large multicenter study, the incidence of PapMI was slightly lower by 14%. This difference might be explained by the inclusion of patients exclusively treated by percutaneous coronary intervention, younger patients, significantly faster reperfusion times, and better antiplatelet activation control (95% of patients received glycoprotein IIb/IIIa inhibitors) in comparison with previous studies.
Delayed reperfusion was an independent predictor for the appearance of PapMI in a previous study. 5 This is partly confirmed in the current study. PapMI was also associated with more pronounced myocardial damage and reperfusion injury as visualized by CMR. Others have already shown that an increased extent of PapMI was accompanied by a stepwise increase in mean infarct transmurality. 8 However, our study is the first providing a comprehensive CMR evaluation of the patient with PapMI including measures of infarct extent and severe reperfusion injury such as microvascular obstruction and hemorrhage. Therefore, our data expand previous findings by demonstrating that the amount of injured myocardium and reperfusion injury is associated with PapMI. The presence of nonanterior infarction was the strongest independent predictor of PapMI. This is in line with previous studies demonstrating that the posterior papillary muscle was involved more frequently than respectively; P<0.001 for all studies), which is probably because of usual single-vessel blood supply of the posterior papillary muscle and dual blood supply of the anterior papillary muscle. Consistent with recent studies, patients with bilateral PapMI had most often left circumflex (55%) lesions. It has been suggested that bilateral PapMI is associated with greater MR, whereas others reported that the association between bilateral PapMI and MR may be attributable to increased lateral wall infarct size. 5, 8 In our study, bilateral PapMI was not associated with greater MR, and more importantly, bilateral PapMI was also not associated with increased MACE rates in comparison with unilateral PapMI.
Prognostic Significance of PapMI
Our study is the first to assess the prognostic significance of PapMI on hard clinical outcome. The current study clearly demonstrates that the presence of PapMI is associated with significantly increased MACE rates. Therefore, our data underscore the importance of PapMI as a marker of poor outcome in the post-MI phase. Importantly, PapMI is correlated with established prognostic markers, such as delayed reperfusion, severe myocardial damage, and reperfusion injury, and might carry prognostic information of these outcome markers. However, PapMI remained an independent predictor of excess MACE in our multivariable Cox regression analysis even after adjustment for these established prognostic markers.
Ischemic MR has generally been identified as an independent predictor of impaired survival in patients with post-MI. 13, 26 Recent studies demonstrated that the size or location (lateral wall infarction) of the MI seems to mainly affect LV remodeling and increased MR as measured early after MI. 4, 8 Our data support the concept that changes associated with remodeling are likely the strongest factors affecting whether a patient will develop MR rather than the mere presence of PapMI. In line with previous studies, PapMI was a nonsignificant predictor of the presence and severity of MR. 4 There is strong experimental evidence that isolated papillary muscle dysfunction in an adequately contractile ventricle is not associated with significant MR. 10 Furthermore, several human studies using echocardiography found no correlation between mild MR and papillary muscle dysfunction. 11, 12 Consequently, echocardiography and CMR studies, including our study, have unequivocally demonstrated that PapMI is not obligatorily associated with ischemic MR.
Another reason for the prognostic relevance of PapMI might be its described potential to generate ventricular arrhythmias in humans. The papillary muscles that lie within a zone of infarction have electrophysiological properties similar to other infarcted myocardium. 4, 11 However, few reports have reported ventricular arrhythmias arising in an infarcted papillary muscle. 
Clinical Implications
The presence of PapMI is associated with considerable excess mortality, suggesting that aggressive therapeutic interventions should be considered. Consequently, all therapeutic options of medical, interventional, and surgical treatment if relevant MR is present should be considered promptly. MR can dynamically change over time and be influenced by further LV remodeling. Therefore, despite the finding of recent studies and the current study that PapMI has only minor effect on ischemic MR, additional research is necessary to examine the independent role of PapMI for predicting long-term MR severity in the remodeled, chronic infarction state.
Limitations
First, the detection of PapMI by CMR is limited to centers with CMR capability and is associated with increased costs. Furthermore, patients with cardiogenic shock and acute heart failure, as well as patient with metallic implants, cannot undergo CMR (≈5%-10% of patients with STEMI). Second, the prognostic significance of PapMI in our study is based on a relative small number of patients with clinical events, and the mechanisms by which PapMI may increase mortality cannot be answered by this study. Third, recent data indicate that in patients with MI, LGE CMR imaging using a short inversion time 6 or a multicontrast LGE CMR sequence 27 may be more sensitive than standard LGE imaging for the detection of PapMI. Therefore, we cannot entirely rule out that we missed PapMIs in some rare cases. However, we used a 3-dimensional LGE CMR sequence with high spatial resolution, which should be sufficient to reliably detect PapMI. 7 Fourth, the severity of MR by transthoracic echocardiography could not be quantitatively evaluated in all patients. However, our study is the largest to date to assess determinants of the presence and severity of MR in acute reperfused STEMI. Finally, MR was assessed within 1 week after MI. Thus, our findings may not apply to longer-term severity of post-MI MR.
Conclusions
The present study demonstrates that PapMI is associated with larger infarcts, less myocardial salvage, impaired LV function, and more pronounced reperfusion injury. Consequently, the presence of PapMI has major prognostic implications in the post-MI phase, independent of established prognostic markers.
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